2021
Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study
Sharma A, Bhatt NS, St Martin A, Abid MB, Bloomquist J, Chemaly RF, Dandoy C, Gauthier J, Gowda L, Perales MA, Seropian S, Shaw BE, Tuschl EE, Zeidan AM, Riches ML, Shah GL. Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study. The Lancet Haematology 2021, 8: e185-e193. PMID: 33482113, PMCID: PMC7816949, DOI: 10.1016/s2352-3026(20)30429-4.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsAllogeneic HSCT recipientsAutologous HSCT recipientsHaematopoietic stem cell transplantation recipientsStem cell transplantation recipientsCOVID-19 diagnosisHSCT recipientsNational Cancer InstituteHigh riskAllogeneic HSCTOverall survivalTransplantation recipientsCOVID-19Cancer InstituteCox proportional hazards modelAggressive treatment measuresSurvival 30 daysObservational cohort studyMarrow Transplant ResearchPoor overall survivalAge 50 yearsOverall survival probabilityPlasma cell disordersMonths of transplantationProportional hazards modelNational Institute
2017
2168
Branagan A, Duffy E, Parker T, Seropian S, Foster C, Zhang L, Verma R, Gan G, Zelterman D, Brandt D, Kortmansky J, Witt D, Dhodapkar M. 2168. Journal Of Clinical And Translational Science 2017, 1: 31-32. PMCID: PMC6799516, DOI: 10.1017/cts.2017.118.Peer-Reviewed Original ResearchPlasma cell disordersInfluenza vaccination strategiesInfluenza vaccinationInfluenza infection ratesVaccination strategiesCell disordersInfluenza infectionClinical correlatesInfection rateInfluenza vaccineRandomized studySingle vaccineDisorder patientsFlu seasonGrade 2 adverse eventsHigh-dose influenza vaccinationHigh-dose influenza vaccineLaboratory-confirmed influenza infectionHigh-dose vaccineSerologic response rateCell-mediated immunityFlu-like illnessNovel vaccination strategiesT cell subpopulationsT cell responsivenessClinical and Serologic Responses After a Two-dose Series of High-dose Influenza Vaccine in Plasma Cell Disorders: A Prospective, Single-arm Trial
Branagan AR, Duffy E, Albrecht RA, Cooper DL, Seropian S, Parker TL, Gan G, Li F, Zelterman D, Boddupalli CS, Zhang L, Verma R, Ferencz TM, Dhodapkar MV. Clinical and Serologic Responses After a Two-dose Series of High-dose Influenza Vaccine in Plasma Cell Disorders: A Prospective, Single-arm Trial. Clinical Lymphoma Myeloma & Leukemia 2017, 17: 296-304.e2. PMID: 28343904, PMCID: PMC5413398, DOI: 10.1016/j.clml.2017.02.025.Peer-Reviewed Original ResearchConceptsPlasma cell disordersSerologic responseInfluenza vaccinationInfluenza vaccineMultiple myelomaCell disordersInfluenza infectionVaccination strategiesHigh-dose influenza vaccineInactivated trivalent influenza vaccineLaboratory-confirmed influenza infectionBooster vaccination strategiesStandard vaccination strategyTwo-dose seriesLaboratory-confirmed influenzaSeasonal influenza vaccinationTrivalent influenza vaccineSingle-arm trialPlasma cell dyscrasiaDisease response assessmentLogistic regression modelsSeroprotection ratesActive therapyAdverse eventsPartial response
2016
Lower Rates of Influenza Infection Following Two Dose Series of High Dose Vaccination in Plasma Cell Disorders: Results of a Randomized, Double-Blind, Placebo-Assisted Clinical Trial
Branagan A, Duffy E, Parker T, Seropian S, Foster C, Zhang L, Verma R, Zelterman D, Gan G, Brandt D, Kortmansky J, Witt D, Ferencz T, Dhodapkar M. Lower Rates of Influenza Infection Following Two Dose Series of High Dose Vaccination in Plasma Cell Disorders: Results of a Randomized, Double-Blind, Placebo-Assisted Clinical Trial. Blood 2016, 128: 2139. DOI: 10.1182/blood.v128.22.2139.2139.Peer-Reviewed Original ResearchHigh-dose influenza vaccinePlasma cell disordersInfluenza vaccinationCell-mediated immunityInfluenza vaccineInfluenza infectionCell disordersClinical correlatesVaccination strategiesPCD patientsRandomized studySingle vaccineClinical trialsDose seriesFlu seasonInfection rateHigh-dose influenza vaccinationLaboratory-confirmed influenza infectionTwo-dose vaccination strategyHigh-dose vaccinationHigh-dose vaccineInfluenza vaccination strategiesPresent randomized studySerologic response rateSeasonal influenza vaccination
2015
Fluzone® High-Dose Influenza Vaccine with a Booster Is Associated with Low Rates of Influenza Infection in Patients with Plasma Cell Disorders
Branagan A, Duffy E, Boddupall C, Albrecht R, Zhang L, Verma R, Cooper D, Seropian S, Parker T, Yao X, Ferencz T, Dhodapkar M. Fluzone® High-Dose Influenza Vaccine with a Booster Is Associated with Low Rates of Influenza Infection in Patients with Plasma Cell Disorders. Blood 2015, 126: 3058. DOI: 10.1182/blood.v126.23.3058.3058.Peer-Reviewed Original ResearchHigh-dose influenza vaccineHigh-dose vaccinePlasma cell disordersNovel vaccination strategiesProtective HAI titersCell-mediated immunityMultiple myeloma patientsNovel vaccine strategiesInfluenza vaccineVaccination strategiesSignificant unmet needInfluenza vaccinationHAI titersPCD patientsCell disordersFlu seasonSecondary endpointsSeroprotection ratesDose vaccineMyeloma patientsVaccine strategiesFlu infectionUnmet needInfection rateGrade 2 adverse events